Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia

Hypertension Research

Volumn 33, Issue 9, 2010, Pages 892-898

  Molvarec, Attila ^a   Szarka, András ^a   Walentin, Szilvia ^b   Szucs, Endre ^a   Nagy, Bálint ^a   Rigó, János ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

electrochemiluminescence immunoassay; PlGF; pre eclampsia; pregnancy; sFlt 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOGENIC FACTOR; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; DNA; FIBRONECTIN; MALONALDEHYDE; NITROGEN; PLACENTAL GROWTH FACTOR; UREA; VASCULOTROPIN RECEPTOR 1; VON WILLEBRAND FACTOR;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTICAL PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; CASE CONTROL STUDY; CELL FREE SYSTEM; CHEMOLUMINESCENCE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ELECTROIMMUNOASSAY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; ENZYME ACTIVITY; FEMALE; GESTATIONAL AGE; HUMAN; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PREECLAMPSIA; PREGNANT WOMAN; PRENATAL GROWTH; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TROPHOBLAST; UREA NITROGEN BLOOD LEVEL;

ADULT; BIRTH WEIGHT; BLOOD PRESSURE; BLOOD UREA NITROGEN; CASE-CONTROL STUDIES; CHEMILUMINESCENT MEASUREMENTS; CREATININE; DNA; FEMALE; FIBRONECTINS; HUMANS; IMMUNOASSAY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RENAL INSUFFICIENCY; TROPHOBLASTS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VON WILLEBRAND FACTOR;

EID: 77956414018     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.92     Document Type: Article

References (56)

1. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565.
2. Roberts JM, Taylor RN, MusciTJ, RodgersGM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-1204.
3. Ohkuchi A, Iwasaki R, Suzuki H, Hirashima C, Takahashi K, Usui R, Matsubara S, Minakami H, Suzuki M. Normal and high-normal blood pressures, but not body mass index, are risk factors for the subsequent occurrence of both preeclampsia and gestational hypertension: a retrospective cohort study. Hypertens Res 2006; 29: 161-167.
4. Molvarec A, Jermendy A, Kovacs M, Prohaszka Z, Rigo J Jr. Toll-like receptor 4 gene polymorphisms and preeclampsia: lack of association in a Caucasian population. Hypertens Res 2008; 31: 859-864.
5. Canto P, Canto-Cetina T, Juarez-Velazquez R, Rosas-Vargas H, Rangel-Villalobos H, Canizales-Quinteros S, Velazquez-Wong AC, Villarreal-Molina MT, Fernandez G, Coral-Vazquez R. Methylenetetrahydrofolate reductase C677T and glutathione S-trans- ferase P1 A313G are associated with a reduced risk of preeclampsia in Maya-Mestizo women. Hypertens Res 2008; 31: 1015-1019.
6. Zafarmand MH, Franx A, Sabour S, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. The M235T variant of the angiotensinogen gene is related to development of self- reported hypertension during pregnancy: the Prospect-EPIC cohort study. Hypertens Res 2008; 31: 1299-1305.
7. Hirashima C, Ohkuchi A, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res 2008; 31: 1541-1548.
8. de Lima TH, Sass N, Mattar R, Moron AF, Torloni MR, Franchim CS, Daher S. Cytokine gene polymorphisms in preeclampsia and eclampsia. Hypertens Res 2009; 32: 565-569.
9. Molvarec A, Kalabay L, Derzsy Z, Szarka A, Halmos A, Stenczer B, Arnaud P, Karadi I, Prohaszka Z, Rigo J Jr. Preeclampsia is associated with decreased serum alpha(2)-HS glycoprotein (fetuin-A) concentration. Hypertens Res 2009; 32: 665-669.
10. Molvarec A, Rigo J Jr, Lazar L, Balogh K, Mako V, Cervenak L, Mezes M, Prohaszka Z. Increased serum heat-shock protein 70 levels reflect systemic inflammation, oxidative stress and hepatocellular injury in preeclampsia. Cell Stress Chaperones 2009; 14: 151-159.
11. Molvarec A, DerzsyZ, Kocsis J, BozeT, Nagy B, Balogh K, Mako V, Cervenak L, Mezes M, Karadi I, Prohaszka Z, Rigo J Jr. Circulating anti-heat-shock- protein antibodies in normal pregnancy and preeclampsia. Cell Stress Chaperones 2009; 14: 491-498.
12. Nagy B, Varkonyi T, Molvarec A, Lazar L, Hupuczi P, Than NG, Rigo J. Leptin gene (TTTC)(n) microsatellite polymorphism in pre-eclampsia and HELLP syndrome. Clin Chem Lab Med 2009; 47: 1033-1037.
13. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007; 74: 100-113.
14. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, SukhatmeVP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
15. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'YoungG, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50: 686-692.
16. Suzuki H, Ohkuchi A, Matsubara S, Takei Y, Murakami M, Shibuya M, Suzuki M, Sato Y. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009; 54: 1129-1135.
17. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145: 4838-4845.
18. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291: R1085-R1093.
19. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
20. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclamp- sia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 2006; 194: 551-556.
21. Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria. Hypertens Pregnancy 2009; 28: 95-108.
22. Molvarec A, Prohaszka Z, Nagy B, Szalay J, Fust G, Karadi I, Rigo J Jr. Association of elevated serum heat-shock protein 70 concentration with transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia: a case-control study. J Hum Hypertens 2006; 20: 780-786.
23. Molvarec A, Rigo J Jr, Nagy B, Walentin S, Szalay J, Fust G, Karadi I, Prohaszka Z. Serum heat shock protein 70 levels are decreased in normal human pregnancy. J Reprod Immunol 2007; 74: 163-169.
24. Joubert K. Standards of the body mass and body length of birth in Hungary on the basis of the 1990-1996 nation-wide liveborn data. Magy Noorv L 2000; 63: 155-163.
25. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, Suzuki M. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010; 33: 422-427.
26. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161 e1-161 e11.
27. Lazar L, Nagy B, Ban Z, Nagy GR, Papp Z. Presence of cell-free fetal DNA in plasma of women with ectopic pregnancies. Clin Chem 2006; 52: 1599-1601.
28. Placer ZA, Cushman LL, Johnson BC. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem 1966; 16: 359-364.
29. Molvarec A, Rigo J Jr, Boze T, Derzsy Z, Cervenak L, Mako V, Gombos T, Udvardy ML, Harsfalvi J, Prohaszka Z. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009; 101:305-311.
30. Paternoster D, Stella A, Simioni P, Trovo S, Plebani P, Girolami A. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet 1994; 47: 215-221.
31. Kitamoto Y, Takeya M, Tokunaga H, Tomita K. Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku J Exp Med 2001; 195: 43-54.
32. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
33. Clark DE, Smith SK, HeY, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540-1548.
34. Johansen M, Redman CW, Wilkins T, Sargent IL. Trophoblast deportation in human pregnancy-its relevance for pre-eclampsia. Placenta 1999; 20: 531-539.
35. Hirashima C, Ohkuchi A, Arai F, Takahashi K, Suzuki H, Watanabe T, Kario K, Matsubara S, Suzuki M. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res 2005; 28: 727-732.
36. ZhongXY, HolzgreveW, HahnS.The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 2002; 21: 77-83.
37. Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, Haines CJ, Redman CW. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999; 45: 184-188.
38. Lazar L, Rigo J Jr, Nagy B, Balogh K, Mako V, Cervenak L, Mezes M, Prohaszka Z, Molvarec A. Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia. BMC Med Genet 2009; 10: 120.
39. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005; 26: 563-573.
40. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005; 46: 1243-1249.
41. Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18: 657-665.
42. Lash GE, Taylor CM, Trew AJ, Cooper S, Anthony FW, Wheeler T, Baker PN. Vascular endothelial growth factor and placental growth factor release in cultured trophoblast cells under different oxygen tensions. Growth Factors 2002; 20: 189-196.
43. Torry DS, Mukherjea D, Arroyo J, Torry RJ. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Investig 2003; 10: 178-188.
44. Wolf M, Shah A, Lam C, Martinez A, Smirnakis KV, Epstein FH, Taylor RN, Ecker JL, Karumanchi SA, Thadhani R. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005; 193: 16-22.
45. Jeyabalan A, Powers RW, Durica AR, Harger GF, Roberts JM, Ness RB. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. Am J Hypertens 2008; 21: 943-947.
46. Suwaki N, Masuyama H, Nakatsukasa H, Masumoto A, Sumida Y, Takamoto N, Hiramatrsu Y. Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia. Am J Obstet Gynecol 2006; 195: 1687-1692.
47. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95: 884-891.
48. Nakada E, Walley KR, Nakada T, Hu Y, von Dadelszen P, Boyd JH. Toll-like receptor-3 stimulation upregulates sFLT-1 production by trophoblast cells. Placenta 2009; 30: 774-779.
49. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
50. Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 2005; 94: 1071-1076.
51. Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H, Yamasaki Y, Masuyama H, Hiramatsu Y, Makino H. Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia. Am J Hypertens 2005; 18: 1181-1188.
52. Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H, Yamasaki Y, Masuyama H, Hiramatsu Y, Makino H. Elevated serum sFlt-1/Ang-2 ratio in women with preeclampsia. Nephron Clin Pract 2007; 106: c43-c50.
53. Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, Watanabe T, Kario K, Suzuki M. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007; 30: 151-159.
54. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG 2010; 117: 314-320.
55. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007; 92: 2672-2679.
56. Nakatsukasa H, Masuyama H, Takamoto N, Hiramatsu Y. Circulating leptin and angiogenic factors in preeclampsia patients. Endocr J 2008; 55: 565-573.